Stock Analiz

Sarepta Therapeutics, Inc. (SRPT) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Sarepta Therapeutics’s revenue went from $5M in fiscal 2016 to $2.2B in fiscal 2025, growth of about 94.9% a year.

Net income in fiscal 2025 was -$713M, a net margin of -32.5%; the best year in this period was 2024 with $235M.

Over the twelve months to September 30, 2026, revenue was $2.0B and net income -$115M.

Free cash flow was -$307M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 106% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $5M162017: $155M172018: $301M182019: $381M192020: $540M202021: $702M212022: $933M222023: $1.2B232024: $1.9B242025: $2.2B25$2.2B
Net income
2016: -$267M162017: -$51M172018: -$362M182019: -$715M192020: -$554M202021: -$419M212022: -$703M222023: -$536M232024: $235M242025: -$713M25-$713M
Free cash flow
2016: -$251M162017: -$244M172018: -$450M182019: -$516M192020: $25M202021: -$482M212022: -$356M222023: -$577M232024: -$343M242025: -$307M25-$307M
EPS (diluted)
2016: $-5.49162017: $-0.86172018: $-5.46182019: $-9.71192020: $-7.11202021: $-5.15212022: $-8.03222023: $-5.80232024: $2.34242025: $-7.1325$-7.13

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2.0B$2.2B$1.9B$1.2B$933M$702M$540M$381M$301M$155M$5M
Gross profit—$2.2B————————$5M
Operating income-$49M-$700M$218M-$268M-$536M-$460M-$564M-$706M-$344M-$172M-$267M
Net income-$115M-$713M$235M-$536M-$703M-$419M-$554M-$715M-$362M-$51M-$267M
EPS (diluted)$-1.37$-7.13$2.34$-5.80$-8.03$-5.15$-7.11$-9.71$-5.46$-0.86$-5.49
R&D$653M$1.5B$805M$877M$877M$771M$722M$561M$402M$167M$188M
Revenue growth—+15.6%+53.0%+33.3%+32.9%+30.0%+41.8%+26.5%+94.7%+2751.6%+332.6%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$186M-$205M-$206M-$501M-$325M-$443M$107M-$456M-$389M-$232M-$246M
Capital spending-$9M-$102M-$137M-$76M-$31M-$38M-$82M-$60M-$61M-$12M-$5M
Free cash flow$176M-$307M-$343M-$577M-$356M-$482M$25M-$516M-$450M-$244M-$251M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks—$25M$0$0———————
Stock-based pay$111M$123M$184M$183M$233M$114M$108M$79M$50M$30M$30M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$940M$1.4B$1.7B$2.0B$2.1B$1.9B$1.1B$1.2B$1.1B$318M
Debt—$1.0B$1.3B$1.4B$1.6B$620M$101M$56M$481M$431M$18M
Equity—$1.1B$1.5B$859M$385M$928M$762M$818M$1.0B$789M$337M
Total assets—$3.3B$4.0B$3.3B$3.1B$3.1B$3.0B$1.8B$1.6B$1.3B$424M
Shares (diluted)106M100M108M92M88M81M78M74M66M59M49M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—98.8%————————97.6%
Operating margin-2.5%-31.8%11.5%-21.5%-57.5%-65.5%-104.5%-185.3%-114.1%-111.0%-4920.3%
Net margin-5.9%-32.5%12.4%-43.1%-75.4%-59.7%-102.6%-187.8%-120.2%-32.8%-4930.2%
FCF margin9.0%-14.0%-18.0%-46.4%-38.2%-68.6%4.7%-135.5%-149.4%-157.8%-4633.1%
ROIC—-25.4%6.9%-9.4%-21.2%-29.7%-51.6%-63.8%-22.7%-11.1%-59.5%
ROE—-62.5%15.4%-62.4%-182.8%-45.1%-72.7%-87.4%-35.1%-6.4%-79.4%

Frequently asked questions

What is Sarepta Therapeutics’s annual revenue?

$2.2B in fiscal 2025 and $2.0B over the twelve months to September 30, 2026.

How much profit does Sarepta Therapeutics make?

Net income was -$713M in fiscal 2025 (net margin -32.5%).

Is Sarepta Therapeutics’s revenue growing?

Yes: revenue rose 15.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.